Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrvinium for Reversal of Precancerous Metaplasia and Dysplasia in the Stomach
NCT06782048Phase 2Not yet recruiting
- Sponsor
- National University Hospital
- Start
- Nov 2026
- Primary completion
- Dec 2029
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of pyrvinium in gastric intestinal metaplasia (IM), gastric dysplasia, sponsored by National University Hospital. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
pyrvinium
03
Conditions
gastric intestinal metaplasia (IM)gastric dysplasia
Beyond the preview
Go deeper on NCT06782048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06782048.